Home
News
Create
Screeners
Insights
Rubicon Research
774.
85
-7.25
(-0.93%)
Market Cap
₹12,765.68 Cr
PE Ratio
62.33
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-0.93%
1M
-0.70%
6M
+23.34%
1Y
+23.34%
5Y
+23.34%
View Company Insights
Latest news about Rubicon Research
Rubicon Research Limited Allots 3,41,815 Equity Shares Under Employee Stock Option Scheme
3 days ago
Rubicon Research Limited allotted 3,41,815 equity shares on March 31, 2026, under its Employee Stock Option Scheme 2022, with approval from the Nomination and Remuneration Committee. The allotment increased the company's paid-up equity share capital to ₹16,50,92,124, comprising 16,50,92,124 shares of ₹1 face value each. The company informed both BSE and NSE about this development in compliance with SEBI regulations.
Rubicon Research Limited Declares Postal Ballot Results with Strong Shareholder Participation
Mar 16, 2026
Rubicon Research Limited Announces Postal Ballot for Independent Director and Secretarial Auditor Appointments
Feb 13, 2026
Rubicon Research Q3 Net Profit Jumps 91% to ₹728M; Management Confident on Growth
Feb 06, 2026
Rubicon Research Board Meeting Outcome: Director Changes & Subsidiary Merger
Feb 03, 2026
More news about Rubicon Research
30
Jan 26
Rubicon Research Limited Reports GST Inspection at Thane and Ambernath Offices
Rubicon Research Limited reported that GST authorities initiated inspection proceedings at its Thane and Ambernath offices on January 30, 2026, under Section 67 of the Maharashtra GST Act. The company is providing full cooperation to officials while business operations continue normally. Based on initial assessment, no material impact on financials or operations is expected from these proceedings.
27
Jan 26
Rubicon Research Limited Schedules Board Meeting on February 3, 2026 for Q3FY26 Financial Results
Rubicon Research Limited has scheduled a board meeting for February 3, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The announcement was made on January 27, 2026, in compliance with SEBI Regulation 29. The company has implemented trading window restrictions from January 1, 2026, which will remain in effect until 48 hours after the financial results announcement, as part of its insider trading prevention measures.
13
Jan 26
Investec Initiates Buy Rating on Rubicon Research with ₹820 Target Price, Projects 47% EPS CAGR
Investec has initiated buy coverage on Rubicon Research with a ₹820.00 target price, projecting 47% EPS CAGR between FY25-FY28. The brokerage highlights the company's ROI-driven strategy achieving over 25% returns and transformation into a specialty-led pharma player. Specialty Generics segment is expected to drive growth with over 10 upcoming launches, increasing gross profit share from 33% to 45-50%.
09
Jan 26
Rubicon Research Limited Appoints Ms. Avani Harish Shah as General Manager for Legal and Compliance
Rubicon Research Limited appointed Ms. Avani Harish Shah as General Manager – Secretarial, Legal & Compliance, effective January 9, 2026. Shah brings over 20 years of corporate legal experience from the IT services industry, including senior roles at LTIMindtree Limited, Capgemini Technologies, and other major corporations. She holds advanced legal qualifications with specialization in Intellectual Property Rights from Government Law College, Mumbai.
06
Jan 26
Rubicon Research Subsidiary AdvaGen Pharma Receives ₹4.19 Crore Tax Demand Notice
Rubicon Research Limited's material subsidiary AdvaGen Pharma Ltd received a ₹4.19 crore tax demand notice from Mumbai Income Tax authorities for assessment year 2021-22. The demand arises from denial of DTAA exemption on ₹10.04 crore income under India-US tax treaty. The subsidiary plans to appeal before ITAT while seeking a stay on the demand, with the company expressing confidence in its legal position.
08
Dec 25
Rubicon Research Limited Shareholders Approve All Six Resolutions in Postal Ballot
Rubicon Research, a pharmaceutical company, announced that its shareholders have approved all six resolutions proposed in a recent postal ballot. The voting, which concluded on December 7, 2025, was conducted through remote e-voting. Shareholder support ranged from 88.81% to 95.18% in favor of the resolutions. The approved resolutions included a promoter agreement and ratification of employee stock option plans. This strong support indicates confidence in the company's management and strategic direction.
13
Nov 25
Rubicon Research Reports Strong Q2 Growth with 56% Jump in Net Profit
Rubicon Research Limited posted strong Q2 FY2026 results with net profit up 56.2% to 539 million rupees and revenue rising 39.2% to 4.12 billion rupees. EBITDA grew 52.9% to 943 million rupees with margin improving to 22.9%. The company's product diversification strategy showed progress with top 5 products now contributing 30% of revenue, down from 34% in Q1. R&D expenses were 11.2% of operating revenue at 475.89 million rupees. Rubicon plans to operationalize its Pithampur plant in mid-2026 to address capacity constraints. The company maintains a strong financial position with 1,514 million rupees in cash and cash equivalents.
13
Nov 25
Rubicon Research Reports Insider Trading Violations, Issues Warnings
Rubicon Research Limited disclosed two cases of insider trading violations. The first involved VP Amol Shamrao Masal selling 30 shares on October 28, 2025, violating contra trade rules and trading window closure. The second case involved HR Head Romola Pinto and relative Vikram N Pinto acquiring 20 shares on October 16, 2025, during a closed trading window. Both trades were deemed inadvertent and of insignificant amounts. The company issued warning letters to the parties involved and reported the incidents to stock exchanges in compliance with SEBI regulations.
Rubicon Research
774.
85
-
7.
25
(-
0.
93
%)
1 Year Returns:
+23.34%
Industry Peers
Sun Pharmaceutical
1,693.60
(-
2.
02
%)
Divis Laboratories
5,856.50
(-
0.
85
%)
Torrent Pharmaceuticals
3,987.20
(-
3.
02
%)
Lupin
2,274.50
(-
0.
02
%)
Dr Reddys Laboratories
1,217.30
(+
0.
64
%)
Cipla
1,192.40
(-
0.
29
%)
Zydus Life Science
864.25
(+
0.
12
%)
Mankind Pharma
1,998.50
(-
0.
14
%)
Aurobindo Pharma
1,333.70
(-
0.
63
%)
Alkem Laboratories
5,258.00
(+
0.
26
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO